Showing papers in "Hepatology in 2000"

TL;DR: This Mayo TIPS model may predict early death following elective TIPS for either prevention of variceal rebleeding or for treatment of refractory ascites, superior to both the Child‐Pugh classification and the Child-Pugh score in predicting survival.

TL;DR: It is shown that in humans, hepatocytes and cholangiocytes can be derived from extrahepatic circulating stem cells, probably of bone marrow origin, and such “transdifferentiation” can replenish large numbers of hepatic parenchymal cells.

TL;DR: Liver biopsy procedures vary greatly in France, hepatitis C is the main indication for liver biopsy at present, US‐guidance should be developed to reduce severe complications, and day‐care procedures increase acceptance of a future biopsy and should also be used more often.

TL;DR: It is concluded that hepatocytes can derive from bone marrow cells after irradiation in the absence of severe acute injury, and the small subpopulation of CD34+lin−Bone marrow cells is capable of such hepatic engraftment.

TL;DR: In this paper, the authors reviewed the standard results from each treatment based on an extensive survey and found that percutaneous ethanol injection (PEI), hepatic resection (HX), and transcatheter arterial embolization (TCAE) have all been used in the treatment of patients with small-sized hepatocellular carcinomas (HCCs).

TL;DR: It is concluded that portal or hepatic venous thrombosis should be regarded as an index for 1 or several prothrombotic disorders, whether or not local precipitating factors or oral contraceptive use are found.

TL;DR: In ALF, the SIRS, whether or not precipitated by infection, appears to be implicated in the progression of encephalopathy, reducing the chances of transplantation and conferring a poorer prognosis.

TL;DR: The natural history of clinically compensated HCV‐graft cirrhosis is shortened when compared with immunocompetent patients, and if retransplantation is considered, it should be performed promptly once decompensation develops.

TL;DR: Patients with advanced CC are more likely to be obese and diabetic compared with age‐ and sex‐matched patients with advanced cirrhosis, which supports the hypothesis that NASH may be an etiological factor in some of the patients with CC.

TL;DR: Past incidence of acute HCV infection was estimated using national seroprevalence data and relative age‐specific incidence data from a sentinel counties surveillance system and showed a large increase in the incidence from the late 1960s to the early 1980s.

TL;DR: The current practice for reporting histopathological evaluation of chronic hepatitis involves separate statements for the cause of disease, if known, for severity of necroinflammatory lesions, and for the extent of parenchymal fibrosis.

TL;DR: Frequent association with prothrombotic states and frequent recanalization on anticoagulation support the recommendation of early anticoAGulation therapy in all patients with recent portal vein thrombosis.

TL;DR: In vivo, RBV‐treated patients showed an increase in aggregated band 3, which was associated with a significantly increased binding of autologous antibodies and complement C3 fragments indicating an erithrophagocytic removal by reticuloendothelial system, suggesting the presence of red cell susceptibility to oxidation.

TL;DR: Evidence is provided that adefovir dipivoxil can be an effective treatment for lamivudine‐resistant HBV mutants as well as wild‐type HBV.

TL;DR: It is concluded that inhibition of viral replication with lamivudine results in a significant improvement of liver function in patients with decompensated HBV cirrhosis, but the long‐term benefits remain uncertain.

TL;DR: A statistically significant relationship was seen between inheritance of high TGF‐β1– and angiotensinogen (AT)‐producing genotypes and the development of progressive hepatic fibrosis and this association persisted after correcting for potential confounders.

TL;DR: Screening for HCC by AFP and/or USG can identify tumors at an early stage, resulting in a higher chance of receiving treatment, and whether it can improve survival requires a further prospective, randomized study.

TL;DR: The combination of IFN‐R is better as first line treatment than IFN monotherapy in comparison with interferon monotherapy, and genotyping and baseline viral load, fibrosis stage, gender, and age are useful predictive factors in determining whether to continue an additional 24 weeks of treatment.

TL;DR: The results suggest that the pattern of reduction in HBV replication is not directly proportional to tissue injury during acute hepatitis B in humans, and it is likely that the immune events central to viral control occur before symptomatic disease.

TL;DR: The hypothesis of a favorable (possibly immunomediated) effect of pregnancy on liver cell necrosis in anti‐HCV–positive women is strongly supported.

TL;DR: The hydrophilic bile acid, ursodeoxycholic acid (UDCA), has been shown when given in a dose of 13 to 15 mg/kg daily for up to 4 years to delay the time to liver transplantation or death and causes a significant improvement of all the biochemical markers of cholestasis but has no beneficial effects on any of the symptoms or associated disorders.

TL;DR: In patients with HBeAg‐negative chronic hepatitis B, long‐term lamivudine therapy is safe and is associated with high biochemical and virologic response rates at the end of the first year, however, response rates tend to decrease with time and breakthroughs due to YMDD mutants accumulate.

TL;DR: In this paper, the authors reexamined a cohort of 1,018 women (median age 24, range 16-38 years at infection) on follow-up for 20 years in 9 representative centers and concluded that formerly healthy young women, without hepatic comorbidity, may clear hepatitis C infection in half of the cases or develop mild chronic hepatitis C with low risk of progression to cirrhosis within 20 years.

TL;DR: Long‐term therapy with lamivudine resulted in maintained improvements in virologic, biochemical, and histologic features of disease in most patients with HBeAg‐negative chronic hepatitis B and in the subgroup of H beAg‐positive patients with high serum transaminase levels.

TL;DR: In conclusion, intermittent administration of IFN suppressed tumor recurrence after treatment with surgery or ethanol injection in patients with HCV‐related chronic liver disease.

TL;DR: Lamivudine‐induced HBeAg seroconversion was not durable in this endemic area of hepatitis B virus infection and the duration of additional lamivUDine therapy after H beAg serconversion significantly affected the posttreatment relapse.